查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1560210

疟疾疫苗市场报告：2030 年趋势、预测与竞争分析

Malaria Vaccine Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

疟疾疫苗趋势与预测

预计到 2030 年，全球疟疾疫苗市场将达到 69 亿美元，2024 年至 2030 年复合年增长率为 18.6%。该市场的主要驱动力是对疟疾疫苗的需求不断增长、前红血球生成疫苗的出现以及对疫苗输送平台的日益偏好。全球疟疾疫苗市场的未来看起来充满希望，医院、专科诊所和居家医疗市场都有机会。

Lucintel 预测，溶血前疫苗预计将在预测期内达到最高成长。

在这个市场中，预计医院将在预测期内实现最高成长。

由于拥有强大的医疗基础设施、疫苗研发的高投资以及主要製造商的存在，北美仍然是最大的地区。

疟疾疫苗市场新趋势

疟疾疫苗市场出现了一些新兴趋势，这些趋势将塑造疟疾预防和控制的未来。这些趋势源于技术的进步、国际合作的加强以及对公共卫生的日益重视。以下的摘要概述了影响市场的关键驱动因素。

  • 全球合作加强：国际伙伴关係变得更加频繁，使得各国之间能够交流研究、资源和专业知识。这一趋势正在导致更有效、更容易获得的疟疾疫苗的开发。已开发国家和开发中国家之间的合作对于应对疟疾流行地区面临的独特挑战尤其重要，从而製定更有针对性和永续的疫苗解决方案。
  • 下一代疫苗：目前许多研究都集中在下一代疟疾疫苗上，该疫苗可以广泛预防多种寄生虫菌株。这些疫苗旨在解决困扰当前疫苗的局限性，例如功效低下和病毒株特异性保护。这一趋势对于长期控制和根除疟疾极为重要，因为它考虑到了疟疾原虫随时间的变化以及对现有药物的抗药性。
  • 疫苗的可近性 人们越来越致力于确保疟疾疫苗对于流行地区的居民来说是有效且负担得起的。这项进展反映出人们认识到解决疫苗分发挑战对于实现全球消除疟疾目标至关重要。这包括降低製造成本、改善供应链以及采用社区为基础的分销策略。
  • 与公共卫生计划的整合：疟疾疫苗越来越多地被纳入更广泛的公共卫生计划，包括针对其他媒介传播疾病的计划。这种方法背离了将疫苗接种作为针对疟疾的临时行动的传统观点。在这种情况下，这样的策略将在整体疟疾控制计画中使用疫苗，其中包括病媒控制措施、教育宣传活动等以及医疗保健基础设施的改善。为了最大限度地提高疟疾疫苗宣传活动的有效性，需要采取这种综合努力。
  • 疫苗输送的进步：无针注射和耐热配方等疫苗输送技术的创新正在成为市场的主要趋势。这些进展对于促进疫苗的接种非常重要，特别是在偏远和资源匮乏的地区。它还有助于限制后勤复杂性，同时确保疫苗有针对性地交付给迫切需要疫苗的贫困社区。

透过技术创新、全球合作和提高疫苗供应，这些新趋势正在重塑疟疾疫苗市场。这些趋势对于实现全球疟疾控制和根除目标的重要性怎么强调也不为过。

疟疾疫苗市场的最新趋势

疟疾疫苗市场正在经历各种重大变化，对产业产生重大影响。这些变化是由技术进步、全球合作以及消除流行地区疟疾的需要所推动的。以下是市场上一些最重要的最新发展。

  • 世界卫生组织对新疫苗核准：世界卫生组织（WHO）最近对新的疟疾疫苗进行了资格预审，标誌着其在全球推广的重要一步。此认证确保该疫苗符合全球公认的安全性和效率要求，并允许其用于大规模免疫工作。这项变化的幅度是巨大的，因为它将加快疟疾流行地区获得疫苗的速度。
  • 基于 mRNA 的疟疾疫苗的进展：mRNA 技术在 COVID-19 疫苗接种中的成功推动了基于 mRNA 的疟疾疫苗的开发。这些疫苗目前正在临床试验中进行评估，初步资料有希望。这项开发的潜在价值是巨大的，因为 mRNA 疫苗有可能比传统疫苗生产方法表现出更高的有效率并且生产速度更快。
  • 扩大疫苗生产能力：最近为扩大疫苗生产能力而进行的投资，特别是在非洲，正在改变疟疾疫苗市场。这些发展包括建立新的製造设施以及与当地製造商合作。这项发展的重要性怎么强调都不为过。这对于透过提高疫苗供应量和减少对进口的依赖来提高区域疫苗供应自给自足至关重要。
  • 推出多系统疫苗：推出针对多种疟疾原虫的疫苗是市场的重要发展。这些疫苗旨在提供更广泛的保护并降低抗药性风险。这具有重大意义，因为它解决了寄生虫多样性问题并提高了疟疾疫苗接种计划的整体有效性。
  • 为疟疾疫苗研究提供更多资金：政府、非政府组织和私人企业的投资正在迅速增加全球疟疾疫苗研究的资金，加速疫苗开发。资金的增加不仅为扩大临床试验创造了空间，而且还为探索新的候选疫苗和开发多种技术创造了空间。在疟疾疫苗市场，资金的增加正在导致快速进步和管道扩张。

上述几点引发了疟疾疫苗产业的重大变革，增加了有效预防和控制疟疾的潜力。这些进步将提供更有效、更容易取得的疫苗选择，并有助于全球采用疟疾疫苗。

疟疾疫苗市场的策略性成长机会

疟疾疫苗市场拥有众多策略性成长机会，特别是公共卫生计画、疫苗开拓和技术进步等关键应用。这些可能性归因于两个主要因素：解决疟疾流行地区问题的迫切需求以及增加全球疫苗覆盖率的机会。以下我们将介绍业务拓展的主要领域。

  • 扩展到公共卫生计划疟疾疫苗接种的公共卫生计划为显着增长和发展提供了途径。政府和组织可以利用疫苗，将其纳入更广泛的卫生活动，包括对抗其他感染疾病。这种方法使疟疾疫苗能够惠及尽可能多的人，同时也是疟疾综合控制策略的一部分。
  • 儿科疫苗开发：为弱势儿童生产具有适合年龄的配方和给药方案的疟疾疫苗是该市场最重要的成长机会之一。为了降低疟疾造成的儿童死亡率，需要製定适合年龄的儿童免疫接种，并采用适当的配方和给药方案。由于儿科疫苗在疾病高发生率地区的重要性，预计对儿科疫苗的关注将推动市场的显着成长。
  • 联合免疫的进展：针对包括疟疾在内的多种疾病的联合疫苗具有策略性成长的潜力。这些疫苗接种可以简化免疫计划并提高免疫率，特别是在资源有限的环境中。鑑于其成本效益，组合疫苗有望广泛使用，因为它们扩大了免疫规划并减轻了多种感染疾病的负担。
  • 提高生产能力：投资扩大疫苗生产能力，特别是在疟疾流行地区，可以带来巨大的成长机会。透过开发本地生产设施并与区域製造商合作，公司可以增加疫苗的供应量，同时减少对进口的依赖。这不仅改善了疫苗的获取，也促进了地方经济的发展。
  • 专注于创新：持续关注基于 mRNA 的疟疾疫苗等创新将成为成长的主要动力。此类技术可以帮助提高疫苗有效性、降低製造成本并加快向受灾者分发疫苗。一旦这些新技术被开发出来并商业化，预计市场将出现显着成长。

疟疾疫苗市场正在因某些策略性成长机会而发生转变，这些机会旨在鼓励发明、改善可及性以及将疫苗与更全面的医疗保健计划相结合。这种潜力将被各种公司和政府机构利用，促进市场的显着成长，从而推动全球消除疟疾的努力。

疟疾疫苗市场推广因素及挑战

疟疾疫苗市场受到技术进步、经济状况、监管原则等一系列因素的影响。了解这些力量有助于公司在市场上成功运作。因此，本演讲总结了影响市场的主要驱动因素和挑战。

推动疟疾疫苗市场的因素是：

1.技术进步：疟疾疫苗市场是由技术进步驱动的，例如基于mRNA的平台和新型佐剂的使用。这些因素为开发更好的疫苗提供了空间，并为开发针对不断变化的疟疾原虫更有效、更适应的疫苗提供了机会。这些技术变革至关重要，因为它们将提高疫苗的效率并增加全球消灭疟疾的机会。

2. 全球卫生倡议：世界卫生组织、联合国儿童基金会和比尔及梅琳达盖兹基金会主导的全球健康倡议正在推动疟疾疫苗市场的扩张。这些组织为疫苗开发、研发和分销网络提供必要的资金、研究支援和供应链。其结果是在疟疾高发生地区更快获得疫苗，支持全球消除疟疾的努力。

3.增加资金筹措：疟疾疫苗的开发和研究随着全球资金的增加而不断增长，是市场成长的基础。我们支持探索新的候选疫苗，扩大临床试验，并透过政府、非政府组织 (NGO) 和私营部门的特定投资资金筹措来建立生产能力。高资金筹措水准也有助于疟疾疫苗市场的快速发展和广泛的产品研发。

4. 疾病负担日益加重：在撒哈拉以南非洲国家和亚洲部分地区，仍有大量人口患有疟疾，因此需要更好的疫苗。这些努力是由降低疟疾发病率和死亡率（主要是儿童和孕妇）的更广泛需求所推动的。疾病负担日益增加的重大影响凸显了全球疟疾控制的迫切性。

5.政府支持：推动该市场销售的主要因素是政府对消除疟疾的大力支持以及将疫苗纳入国家免疫规划。在大多数情况下，流行地区政府越来越重视将疫苗接种策略纳入更广泛的公共卫生框架。政府的支持使得大规模的免疫工作得以进行，同时维持了对疫苗的需求。

疟疾疫苗市场的挑战包括：

1. 监管障碍：应对复杂的法规环境是疟疾疫苗市场的重大挑战。新疫苗技术必须满足严格的安全性和有效性标准，这可能会减慢核准和分发过程。监管障碍的影响很大，因为它们阻碍了最需要疫苗的地区获得疫苗。

2. 製造成本高：製造复杂的疟疾疫苗，特别是采用新技术的疫苗，高成本，限制了该产业的扩张。这些成本可能使它们难以承受且难以获得，特别是对于低收入群体而言。高製造成本的影响是巨大的，限制了疫苗接种计划的覆盖范围，并减缓了国际上消除疟疾的进展。

3. 供应链限制：在疟疾流行地区，供应链基础设施薄弱限制了疫苗的供应和使用。只有当疫苗到达偏远和资源匮乏地区时，免疫宣传活动才能成功。供应链限制的影响是巨大的，因为它们会导致疫苗推出的延迟，并破坏有效控制疟疾的努力。

疟疾疫苗市场的主要驱动因素和挑战将塑造疟疾预防和控制的未来。儘管市场成长是由技术进步和资金筹措增加所推动的，但也存在明显的障碍，例如监管限制、高製造成本和供应链限制。这些都是疟疾疫苗市场持续发展需要平衡的因素，有助于实现消灭疟疾的全球目标。

疟疾疫苗细分市场

这项研究按类型、药物、最终用途和地区对全球疟疾疫苗进行了预测。

各国疟疾疫苗市场前景

由于研究开拓、研究经费增加以及控制流行地区疟疾的需要，疟疾疫苗市场正在经历重大发展。这些发展由德国、印度、美国、中国和日本等主要市场主导，每个市场对全球努力的贡献都不同。新兴国家的近期趋势如下。

  • 美国：疟疾疫苗研究的资金正在增加，包括比尔及梅琳达盖兹基金会和美国国立卫生研究院在内的各种组织都发挥关键作用。迄今为止的进展包括下一代疟疾疫苗临床试验的进展，重点是提高其功效并扩大针对多种疟疾菌株的覆盖范围。此外，美国在开发新佐剂以提高疫苗效率方面发挥主导作用。
  • 透过与非洲国家的合作，中国在疟疾疫苗研发领域取得了重大进展。这也包括里程碑，例如本地生产的疫苗的后期临床试验。中国的「一带一路」倡议还可以在全部区域分发这些疫苗，使其成为一项致力于降低疟疾相关发病率和死亡率的全球卫生倡议，这证明了中国作为合作伙伴的重要性。
  • 德国 德国与国际组织和非洲研究中心在疟疾疫苗研究的合作是最新进展之一。我们支持不同的疫苗来应对引起疟疾的寄生虫生命週期的不同阶段。根据对健康和疾病控制的全球承诺，德国的目标是使这些疫苗具有可扩展性和可负担性，以便在全球广泛使用。
  • 印度 印度在疟疾药物领域取得了重大进展，并取得了多项进展，包括在该国开始本土疫苗的临床试验。与印度政府合作的全球卫生组织也致力于向高流行地区分发疫苗。这显示印度正在努力实现无疟疾社会，并已成为全球疫苗市场的关键参与者。
  • 日本 日本凭藉其先进的生物技术部门，在疟疾疫苗研究中发挥重要作用。最近的进展包括日本和非洲科学家共同进行的临床试验以及针对亚洲和非洲流行的特定疟疾菌株的疫苗的开发。为了实现全球热带医学目标，日本研究人员的贡献是提高整体疫苗效率并扩大世界各地疟疾流行地区获得疟疾预防措施的机会。

常问问题

Q.1 疟疾疫苗的市场规模有多大？

A1. 到 2030 年，全球疟疾疫苗市场预计将达到 69 亿美元。

Q.2 疟疾疫苗市场的成长预测如何？

A2. 2024年至2030年，全球疟疾疫苗市场预计将以18.6%的复合年增长率成长。

Q.3 影响疟疾疫苗市场成长的关键驱动因素有哪些？

A3. 该市场的主要驱动力是对疟疾疫苗的需求不断增长、前红系疫苗的出现以及对疫苗输送平台的日益偏好。

Q4.市场的主要细分市场是：

A4. 疟疾疫苗市场前景广阔，医院、专科诊所和居家医疗市场都有机会。

Q5.市场的主要企业是：

A5. 主要疟疾疫苗公司如下：

  • Actiza Pharmaceutical
  • AdvaCare Pharma
  • Ipca Laboratories
  • Bliss GVS Pharma
  • GeoVax
  • Sumaya Biotech
  • VLP Therapeutics
  • OSIVAX
  • AJANTA PHARMA
  • Strides Pharma Science

Q6.未来最大的细分市场是什么？

A6.Lucintel 预测，前红血球在预测期内将经历最高的成长。

Q7. 未来五年预计哪些地区的市场成长最大？

A7. 由于其强大的医疗基础设施、对疫苗研发的高投资以及主要製造商的存在，北美将继续成为最大的地区。

Q8. 可以客製化报告吗？

A8. 是的，Lucintel 提供 10% 的客製化服务，无需额外付费。

目录

第一章执行摘要

第二章全球疟疾疫苗市场：市场动态

  • 简介、背景、分类
  • 供应链
  • 产业驱动因素与挑战

第三章 2018-2030年市场趋势及预测分析

  • 宏观经济趋势（2018-2023）与预测（2024-2030）
  • 全球疟疾疫苗市场趋势（2018-2023）与预测（2024-2030）
  • 全球疟疾疫苗市场，依类型
    • 红系前期
    • 红血球
    • 多抗原
    • 其他的
  • 全球疟疾疫苗市场（按药物）
    • 疟疾原虫
    • 疟疾原虫
    • 依蚊
  • 全球疟疾疫苗市场（依最终用途）
    • 医院
    • 专科诊所
    • 居家护理
    • 其他的

第四章 2018-2030年区域市场趋势及预测分析

  • 全球疟疾疫苗市场（按地区）
  • 北美疟疾疫苗市场
  • 欧洲疟疾疫苗市场
  • 亚太疟疾疫苗市场
  • 其他区域疟疾疫苗市场

第五章 竞争分析

  • 产品系列分析
  • 业务整合
  • 波特五力分析

第六章 成长机会与策略分析

  • 成长机会分析
    • 全球疟疾疫苗市场的成长机会（按类型）
    • 全球疟疾疫苗市场的成长机会（按药物）
    • 全球疟疾疫苗市场成长机会（依最终用途）
    • 全球疟疾疫苗市场成长机会（按地区）
  • 全球疟疾疫苗市场的新趋势
  • 战略分析
    • 新产品开发
    • 扩大全球疟疾疫苗市场产能
    • 全球疟疾疫苗市场的合併、收购和合资企业
    • 认证和许可

第七章主要企业概况

  • Actiza Pharmaceutical
  • AdvaCare Pharma
    • Ipca Laboratories
  • Bliss GVS Pharma
  • GeoVax
  • Sumaya Biotech
  • VLP Therapeutics
  • OSIVAX
  • AJANTA PHARMA
  • Strides Pharma Science
简介目录

Malaria Vaccine Trends and Forecast

The future of the global malaria vaccine market looks promising with opportunities in the hospital, specialty clinic, and homecare markets. The global malaria vaccine market is expected to reach an estimated $6.9 billion by 2030 with a CAGR of 18.6% from 2024 to 2030. The major drivers for this market are growing demand for malaria vaccines, emergence of pre-erythrocytic vaccines, and rising preference for vaccine delivery platforms.

Lucintel forecasts that pre-erythrocytic is expected to witness highest growth over the forecast period.

Within this market, hospital is expected to witness highest growth over the forecast period.

North America will remain the largest region due to existence of robust healthcare infrastructure, high investment in vaccines research and development, and presence of key manufacturers in the region.

Emerging Trends in the Malaria Vaccine Market

There are several emerging trends that are shaping the future of malaria prevention and control in the malaria vaccine market. These trends arise from technological progress, increased global cooperation, and higher emphasis on public health. The following summaries provide an overview of major drivers affecting the market.

  • Increased Global Collaboration: International partnerships have become more frequent allowing for the exchange of research, resources, and know-how across countries. This trend is leading to the development of more effective and accessible malaria vaccines. Collaboration between developed and developing nations is particularly important in addressing unique challenges faced by malaria endemic zones leading to more focused and sustainable vaccine solutions.
  • Next-Generation Vaccines: A lot of research now focuses on next-generation malaria vaccines that can broadly protect against several strains of the parasite. These vaccines aim to address the limitations afflicting current vaccines such as low efficacy or strain-specific protection. This trend is very vital for the long-term control and eradication of malaria since it accounts for changes like the malaria parasite over time as well as its resistance to available drugs.
  • The Focus on Vaccine Accessibility: There is a growing push to ensure malaria vaccines are effective and affordable to populations in endemic regions. The trend reflects the realization that addressing vaccine distribution challenges is important to achieve global malaria elimination targets. This encompasses reducing production costs, improving supply chains, and adopting community-based distribution strategies.
  • Integration with Public Health Programs: Malaria vaccines are increasingly being integrated into broader public health programs, including those targeting other vector-borne diseases. This approach is a departure from traditional thinking which sees vaccination as a perfunctory action against malaria. In this case, such a strategy involves the use of vaccines alongside vector control measures and educational campaigns among others within an overall plan for fighting malaria that may also include improved healthcare infrastructure. These integration efforts are necessary to maximize the impact of malaria vaccination campaigns.
  • Advancements in Vaccine Delivery: Innovations in vaccine delivery technologies like needle-free injections and thermostable formulations are emerging as key trends in the market. These developments have notable importance for enhancing the uptake of vaccines, particularly in remote areas and resource-poor settings. Furthermore, they help curb logistical complexity while ensuring targeted delivery to needy societies that require vaccines urgently.

By increasing innovation, global cooperation, and accessibility of vaccines, these emerging trends are reshaping the malaria vaccine market. The importance of these trends in achieving global malaria control and eradication goals cannot be overstated.

Recent Developments in the Malaria Vaccine Market

The malaria vaccine market is undergoing various significant changes that have impacted the industry greatly. These developments are driven by technological advancements, global collaborations, and the need to control malaria in endemic areas. Here are some of the most important recent developments in the market.

  • WHO Prequalification of New Vaccines: The World Health Organization (WHO) recently pre-qualified new malaria vaccines, representing an important stage in their global deployment. This qualification ensures that the vaccines satisfy globally accepted safety and efficiency requirements so that they can be used in large-scale immunization initiatives. The magnitude of this change is immense since it hastens access to vaccines within malaria-endemic regions.
  • Advancement of mRNA-based Malaria Vaccines: The development of mRNA-based malaria vaccines has been buoyed by the success of mRNA technologies in COVID-19 vaccinations. Currently, these vaccines are being evaluated through clinical trials and have early data showing promise. The potential value of this development is substantial because mRNA vaccines may offer higher efficacy rates and be manufactured faster than traditional vaccine methods.
  • Expanding Vaccine Manufacturing Capabilities: Recent investments in expanding vaccine manufacturing capabilities, particularly in Africa, are transforming the malaria vaccine market. Such developments include setting up new production facilities and partnering with local manufacturers. The importance of this development cannot be overemphasized as it is critical for improving vaccine availability and reducing dependency on importations, thus enhancing regional self-sufficiency in vaccine supply.
  • Introduction of Multi-Strain Vaccines: The introduction of vaccines that target multiple strains of the malaria parasite is a key development in the market. These vaccines aim to provide broader protection and reduce the risk of resistance. This has had a significant impact because it addresses the problem of parasite diversity and improves the overall efficacy of malaria vaccination programs.
  • More Funding for Malaria Vaccine Research: The worldwide surge in funding for malaria vaccine research led by governments, NGOs, and private sector investments is speeding up vaccine development. With these increased resources, there has been room to explore new candidates for vaccines as well as develop diverse technologies besides broadening clinical trials. An enlarged fraction of funds has led to rapid advancements as well as pipeline expansion experienced in the market for malaria vaccines.

The above-mentioned points are catalysts for major transformations in the malaria vaccine industry, thereby enhancing the potential for effective malaria prevention and management. These advancements will likely result in stronger and more accessible vaccine options, thus contributing to the global campa

Strategic Growth Opportunities for Malaria Vaccine Market

There are numerous strategic opportunities for growth in the malaria vaccine market, especially about key applications like public health programs, vaccine development, and technological advancements. These possibilities are caused by two main factors: the pressing need to address malaria endemic areas and a chance to increase global coverage of vaccines. The next summaries highlight major areas for business expansion.

  • Expanding into Public Health Programs: Public health programs in malaria vaccination will provide an avenue for tremendous growth and development. Governments and organizations can make use of their vaccines by integrating them into wider health initiatives such as those that address other infectious diseases. This approach helps ensure that malaria vaccines reach as many people as possible while also making sure that they form part of a comprehensive malaria-fighting strategy.
  • Development of Pediatric Vaccines: Producing age-appropriate formulations and dosage schedules of malaria vaccines for vulnerable children represents one of the most important opportunities for growth in this market. To lower child mortality rates due to malaria, age-specific pediatric immunizations should be developed with appropriate formulations and dosing schedules. By focusing on pediatric vaccines, it is expected that there will be significant market growth since this particular demographic is important in areas where there is a high prevalence rate of the disease.
  • Progress in Combination Immunization: Combination vaccines that target multiple diseases, including malaria, have the potential for strategic growth. These shots streamline immunization schedules and enhance vaccination coverage, particularly in resource-limited settings. Given their cost-effectiveness, combination vaccines are expected to gain traction as they expand immunization programs and reduce the burden of multiple infectious diseases.
  • Manufacturing Capacity Increase: One can find a vital growth opportunity in investing in vaccine manufacturing capacity expansion, particularly in malaria-endemic areas. Through developing local production facilities and partnering with regional manufacturers, firms can increase vaccine availability while reducing reliance on imports. This way improves not only vaccine access but also encourages economic development at a local level.
  • Technological Innovation Focus: The continued emphasis on technological innovation such as mRNA-based malaria vaccines is a major driver for growth. Such technologies will help enhance vaccine efficacy, lower production expenses, and speed up the distribution of vaccines to suffering populations. Massive market growth is expected when these new technologies are developed and commercialized.

The malaria vaccine market is being transformed by certain strategic growth opportunities, which are aimed at encouraging invention, increasing access, and merging vaccines with more comprehensive healthcare schemes. Such possibilities will be exploited by various businesses and governmental organizations, thus fostering a notable increase in the market boosting worldwide efforts towards eliminating malaria.

Malaria Vaccine Market Driver and Challenges

The market for malaria vaccine is influenced by a series of factors such as technological progress, economic terms, and regulatory principles. Knowing these forces will help a firm to operate well in the market. Therefore, this presentation gives summaries of the main drivers and challenges that affect the market.

The factors responsible for driving the malaria vaccine market include:

1. Technological Advancements: The malaria vaccine market is driven by technological advancements such as the use of mRNA-based platforms and novel adjuvants. These factors give room for better vaccines and offer opportunities for the development of more effective, adaptable vaccines against changing malaria parasites. The impact of these technological changes is critical since they boost vaccine efficiency and increase chances for global malaria elimination.

2. Global Health Initiatives: The expansion of the malaria vaccine market is being pushed by international health initiatives led by WHO, UNICEF, Bill & Melinda Gates Foundation. These organizations provide crucial funding, research assistance, and supply chains for vaccine discovery, development, and distribution networks that are integral to this process. This results in faster access to vaccines in regions with high rates of malaria; thus supporting global efforts towards eradicating malaria in the world.

3. Increased Funding: Malaria vaccine development and research, which is globally funded and has grown, forms the basis of market growth. It supports the search for new vaccine candidates, expansion of clinical trials, and capacity building for production through fundraising by governments, nongovernmental organizations (NGOs), and private sector investments. The high funding levels also contribute to rapid developments as well as a broader pipeline in the malaria vaccine market.

4. Rising Disease Burden: Among others in sub-Saharan Africa and certain Asian countries, there are still large numbers of people suffering from malaria and this is a reason why they seek good vaccines. These efforts are driven by the widespread need to reduce malaria-related morbidity and mortality experienced mainly among children and pregnant women. The significant impact of increasing disease burden emphasizes urgency towards global malaria control.

5. Government Support: The main factor driving sales in this market is strong government support to achieve the elimination of malaria as well as the integration of vaccines into national immunization programs. In most cases, governments in endemic areas have increased their focus on vaccination strategies to be integrated within wider public health frameworks. Governments' support ensures that large-scale immunization efforts can occur while keeping up demand for vaccines being met.,

Challenges in the malaria vaccine market are:

1. Regulatory Hurdles: For the malaria vaccine market, navigating intricate regulatory environments is a significant challenge. Stringent safety and efficacy standards have to be met for new vaccine technologies, which can slow down approval and distribution processes. The impact of regulatory hurdles is great as they hinder the accessibility of vaccines in areas where they are needed most.

2. High Production Costs: The high costs associated with manufacturing sophisticated malaria vaccines, especially those that incorporate novel technologies, limit the expansion of the industry. The expenses can make them unaffordable and inaccessible, particularly in low-income areas. The impact of high production costs is significant as it restricts vaccination programs' coverage and slows international progress toward the elimination of malaria.

3. Supply Chain Limitations: Poor supply chain infrastructure in regions with endemic malaria restricts the availability and utilization of vaccines. Immunization campaigns can only succeed if vaccines reach remote and resource-poor places. The effect of supply chain limitations is considerable because it causes delays in vaccine rollouts and undermines efforts to control malaria effectively.

The major drivers and challenges in the malaria vaccine market are shaping the future of malaria prevention and control. Market growth is driven by technological advancements as well as increased funding; however, there are notable obstacles including regulatory restrictions, high production costs, and supply chain constraints. Those are the factors that need to be balanced for continuous progress of the malaria vaccine market which could help in reaching global goals for malaria eradication.

List of Malaria Vaccine Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies malaria vaccine companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the malaria vaccine companies profiled in this report include-

  • Actiza Pharmaceutical
  • AdvaCare Pharma
  • Ipca Laboratories
  • Bliss GVS Pharma
  • GeoVax
  • Sumaya Biotech
  • VLP Therapeutics
  • OSIVAX
  • AJANTA PHARMA
  • Strides Pharma Science

Malaria Vaccine by Segment

The study includes a forecast for the global malaria vaccine by type, agent, end use, and region.

Malaria Vaccine Market by Type [Analysis by Value from 2018 to 2030]:

  • Pre-Erythrocytic
  • Erythrocytic
  • Multi-Antigen
  • Others

Malaria Vaccine Market by Agent [Analysis by Value from 2018 to 2030]:

  • Plasmodium Falciparum
  • Plasmodium Vivax
  • Anopheles Species

Malaria Vaccine Market by End Use [Analysis by Value from 2018 to 2030]:

  • Hospitals
  • Specialty Clinics
  • Homecare
  • Others

Malaria Vaccine Market by Region [Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

Country Wise Outlook for the Malaria Vaccine Market

Advances in research, increased funding, and the need to combat malaria in endemic areas have resulted in considerable development of the malaria vaccine market. These developments are being led by key markets including Germany, India, the United States, China, and Japan which each contribute differently toward the global effort. The summaries below provide insights into recent developments within these countries.

  • United States: Funding for malaria vaccine research has increased with various organizations such as Bill & Melinda Gates Foundation and NIH playing a major role. Progress made so far includes advancements made in clinical trials for next-generation malaria vaccines that focused on improving their efficacy and providing broader coverage against multiple strains of malaria. Additionally, the USA is leading in new adjuvant development to enhance vaccine efficiency.
  • China: In collaboration with African countries, China has advanced significantly in the field of developing a vaccination against malaria. These include milestones like late-stage clinical trials of locally produced vaccines. China's Belt and Road Initiative also makes available these vaccines for distribution across malaria-endemic regions thus illustrating its significance as a partner in global health initiatives emphasizing reduction of malaria-related morbidity and mortality rates.
  • Germany: The collaboration of Germany with international bodies and African research centers on malaria vaccine research is one of the recent developments. They have supported different vaccines to deal with various stages in the life cycle of a parasite causing malaria. It aims to make these vaccines scalable and affordable so that they can be widely used globally in line with its worldwide commitment to health and disease control.
  • India: India has made remarkable progress in the area of malaria drugs with some strides such as; launching clinical trials for native vaccines within her territory. Global health organizations partnering with the Indian government are also emphasizing the distribution of vaccines across high-endemic areas. This demonstrates how India is working towards attaining a malaria-free society, thus making it an important player in the global vaccine market.
  • Japan: Japan plays a vital role in research on malaria vaccines through its advanced biotechnology sector. Some recent developments include clinical trials conducted together by Japanese scientists and their African counterparts as well as the development of specific vaccines targeting particular strains of malaria prevalent in Asia and Africa. Achieving global tropical medicine objectives, Japanese researchers' contribution consists of increasing overall vaccine efficiency as well as enlarging accessibility to preventive measures against malaria among infected regions worldwide.

Features of the Global Malaria Vaccine Market

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Malaria vaccine market size by type, agent, end use, and region in terms of value ($B).

Regional Analysis: Malaria vaccine market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different types, agents, end uses, and regions for the malaria vaccine market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the malaria vaccine market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

FAQ

Q.1 What is the malaria vaccine market size?

Answer: The global malaria vaccine market is expected to reach an estimated $6.9 billion by 2030.

Q.2 What is the growth forecast for malaria vaccine market?

Answer: The global malaria vaccine market is expected to grow with a CAGR of 18.6% from 2024 to 2030.

Q.3 What are the major drivers influencing the growth of the malaria vaccine market?

Answer: The major drivers for this market are growing demand for malaria vaccines, emergence of pre-erythrocytic vaccines, and rising preference for vaccine delivery platforms.

Q4. What are the major segments for malaria vaccine market?

Answer: The future of the malaria vaccine market looks promising with opportunities in the hospital, specialty clinic, and homecare markets.

Q5. Who are the key malaria vaccine market companies?

Answer: Some of the key malaria vaccine companies are as follows:

  • Actiza Pharmaceutical
  • AdvaCare Pharma
  • Ipca Laboratories
  • Bliss GVS Pharma
  • GeoVax
  • Sumaya Biotech
  • VLP Therapeutics
  • OSIVAX
  • AJANTA PHARMA
  • Strides Pharma Science

Q6. Which malaria vaccine market segment will be the largest in future?

Answer: Lucintel forecasts that pre-erythrocytic is expected to witness highest growth over the forecast period.

Q7. In malaria vaccine market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region due to existence of robust healthcare infrastructure, high investment in vaccines research and development, and presence of key manufacturers in the region.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the malaria vaccine market by type (pre-erythrocytic, erythrocytic, multi-antigen, and others), agent (plasmodium falciparum, plasmodium vivax, and anopheles species), end use (hospitals, specialty clinics, homecare, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Malaria Vaccine Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Malaria Vaccine Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Malaria Vaccine Market by Type
    • 3.3.1: Pre-Erythrocytic
    • 3.3.2: Erythrocytic
    • 3.3.3: Multi-Antigen
    • 3.3.4: Others
  • 3.4: Global Malaria Vaccine Market by Agent
    • 3.4.1: Plasmodium Falciparum
    • 3.4.2: Plasmodium Vivax
    • 3.4.3: Anopheles Species
  • 3.5: Global Malaria Vaccine Market by End Use
    • 3.5.1: Hospitals
    • 3.5.2: Specialty Clinics
    • 3.5.3: Homecare
    • 3.5.4: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Malaria Vaccine Market by Region
  • 4.2: North American Malaria Vaccine Market
    • 4.2.1: North American Malaria Vaccine Market by Type: Pre-Erythrocytic, Erythrocytic, Multi-Antigen, and Others
    • 4.2.2: North American Malaria Vaccine Market by End Use: Hospitals, Specialty Clinics, Homecare, and Others
  • 4.3: European Malaria Vaccine Market
    • 4.3.1: European Malaria Vaccine Market by Type: Pre-Erythrocytic, Erythrocytic, Multi-Antigen, and Others
    • 4.3.2: European Malaria Vaccine Market by End Use: Hospitals, Specialty Clinics, Homecare, and Others
  • 4.4: APAC Malaria Vaccine Market
    • 4.4.1: APAC Malaria Vaccine Market by Type: Pre-Erythrocytic, Erythrocytic, Multi-Antigen, and Others
    • 4.4.2: APAC Malaria Vaccine Market by End Use: Hospitals, Specialty Clinics, Homecare, and Others
  • 4.5: ROW Malaria Vaccine Market
    • 4.5.1: ROW Malaria Vaccine Market by Type: Pre-Erythrocytic, Erythrocytic, Multi-Antigen, and Others
    • 4.5.2: ROW Malaria Vaccine Market by End Use: Hospitals, Specialty Clinics, Homecare, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Malaria Vaccine Market by Type
    • 6.1.2: Growth Opportunities for the Global Malaria Vaccine Market by Agent
    • 6.1.3: Growth Opportunities for the Global Malaria Vaccine Market by End Use
    • 6.1.4: Growth Opportunities for the Global Malaria Vaccine Market by Region
  • 6.2: Emerging Trends in the Global Malaria Vaccine Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Malaria Vaccine Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Malaria Vaccine Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Actiza Pharmaceutical
  • 7.2: AdvaCare Pharma
    • 7.1.1: Ipca Laboratories
  • 7.4: Bliss GVS Pharma
  • 7.5: GeoVax
  • 7.6: Sumaya Biotech
  • 7.7: VLP Therapeutics
  • 7.8: OSIVAX
  • 7.9: AJANTA PHARMA
  • 7.10: Strides Pharma Science